Abstract
Methods based on capillary zone electrophoresis (CZE) and electrokinetic chromatography (EKC) are developed for the separation of motexafin gadolinium (MGd, Xcytrin®), a novel redox-active drug, under development for cancer therapy, and two closely related metallotexaphyrin impurities, called PCI-0400 and PCI-0430. The three metallotexaphyrins are baseline resolved using EKC in a separation solution containing 400-mM cetyltrimethyl ammonium bromide, 50-mM phosphoric acid, and 20% methanol. Detection is achieved using native laser-induced fluorescence (LIF) by exciting at 488 nm and collecting emission at 750 nm. Analysis of a representative clinical batch of MGd using EKC combined with native LIF allowed for the detection of PCI-0400 and PCI-0430 along with nine other possible MGd impurities, each of which is present at approximately 0.1% (total weight of the sample).
| Original language | English |
|---|---|
| Pages (from-to) | 819-824 |
| Number of pages | 6 |
| Journal | Journal of Separation Science |
| Volume | 25 |
| Issue number | 13 |
| DOIs | |
| Publication status | Published - Sept 2002 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Capillary electrophoresis
- Electrokinetic chromatography
- Expanded porphyrins
- Metallotexaphyrins
- Motexafin gadolinium
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver